Evidence map›Paper›PMID 35640086›Full record

ArticleAging2022

Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy.

Haixiao Wu, Guijun Xu, Zhijun Li, Yao Xu, Yile Lin, Vladimir P Chekhonin, Karl Peltzer, Jun Wang, Shu Li, Huiyang Li and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Haixiao WuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Guijun XuThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Zhijun LiTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yao XuTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yile LinThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Vladimir P ChekhoninThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Karl PeltzerThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Jun WangDepartment of Oncology, Radiology and Nuclear Medicine, Medical Institute of Peoples' Friendship University of Russia, Moscow, Russian Federation.
Shu LiThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Huiyang LiThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Jin ZhangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yuan XueThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Wenjuan MaTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Xin WangThe Sino-Russian Joint Research Center for Bone Metastasis in Malignant Tumor, Tianjin, China.
Chao ZhangTianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Tianjin Medical University Cancer Institute and Hospital · CNTianjin Medical University General Hospital · CNArmy Medical University · CNFederal Medical Research Centre for Psychiatry and Narcology · RUPeoples' Friendship University of Russia · RUTianjin University · CNTianjin University of Traditional Chinese Medicine · CNUniversity of the Free State · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo explore the trends of plasma drug concentration changes after high-dose methotrexate (MTX) treatment of osteosarcoma (OS), analyse the risk factors for leukopenia (LP) after MTX treatment, and establish a LP prediction nomogram.

methodsA total of 35 OS patients at Tianjin Medical University Cancer Institute and Hospital between 2017 and 2021 were collected (the construction cohort). Another 12 OS patients between 2019 and 2021 in P.A. Hertsen Moscow Oncology Research Center were involved (the external validation cohort). Peripheral venous blood MTX concentration (C

resultsA total of 128 MTX chemotherapy cycles from 35 OS patients were included. Female, Ki-67>20%, C

conclusionsFemale, C

Indexed as

Bone NeoplasmsLeukopeniaOsteosarcomaFemaleHumansKi-67 AntigenMethotrexateNomogramsKi-67 AntigenMethotrexateleukopeniamethotrexatenomogramosteosarcomarisk factor

Identifiers

PMID35640086
PMCPMC9271309
OpenAlexW4281622678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.